Overview
GlaxoSmithKline Wind Project (Turbine 4) is a 2.5 MW onshore wind turbine in the United Kingdom, operated by pharmaceutical company GlaxoSmithKline to power its operations with renewable energy.
GlaxoSmithKline Wind Project (Turbine 4) is an onshore wind turbine located in the United Kingdom, specifically at coordinates 55.5929° N, -4.6182° W. With a capacity of 2.5 MW, it is a small-scale wind installation typical of corporate renewable energy projects. The turbine is owned and operated by GlaxoSmithKline, a global pharmaceutical company, and is part of a broader trend of corporate investment in onsite renewable generation. The turbine operates under the UK's regulatory framework for renewable energy, which includes the Contracts for Difference (CfD) scheme and the Renewables Obligation (RO). These mechanisms support wind energy deployment by providing price stability and revenue support. The UK has a mature wind energy sector, with onshore wind being a well-established technology, though new onshore wind projects face planning and grid connection challenges. This project contributes to GlaxoSmithKline's renewable energy targets and reduces the company's carbon footprint. By generating electricity onsite, it also helps alleviate grid demand and supports the UK's goal of achieving net-zero emissions by 2050. The turbine's location in a region with good wind resources ensures efficient power generation.
Environmental context
Onshore wind turbines like this one can have visual impacts on the landscape and may affect local bird and bat populations through collision risks. However, proper siting and mitigation measures can reduce these impacts. The turbine also contributes to reducing greenhouse gas emissions by displacing fossil fuel-based electricity generation, supporting the UK's transition to a low-carbon energy system.
Frequently asked questions
The turbine is located in the United Kingdom at coordinates 55.5929° N, -4.6182° W, likely in Scotland near the coast.
The turbine has a capacity of 2.5 megawatts (MW), which is typical for a single modern onshore wind turbine.
The turbine is owned and operated by GlaxoSmithKline (GSK), a global pharmaceutical company, as part of its corporate renewable energy initiatives.
The UK supports onshore wind through the Contracts for Difference (CfD) scheme and the Renewables Obligation (RO), which provide revenue stability and incentives for renewable generation.
By generating clean electricity onsite, the turbine reduces GSK's reliance on grid power from fossil fuels, lowering carbon emissions and supporting the UK's net-zero target by 2050.